topical

Late-Stage Trial Initiated for Topical Reduction of Undereye Bags

Late-Stage Trial Initiated for Topical Reduction of Undereye Bags

Biotechnology company Topokine Therapeutics has initiated a Phase 2b/3 study of its lead product, XAF5 Ointment, for the reduction of steatoblepharon (undereye bags). Applied to the lower eyelids once nightly, the topical treatment penetrates the skin and acts pharmacologically on fat cells to shrink eye bags as an alternative to blepharoplasty surgery.